ZEVRA THERAPEUTICS, INC. — Director's Dealing 2021

Nov 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: KEMPHARM, INC (KMPH)
CIK: 0001434647
Period of Report: 2021-11-10

Reporting Person: Pascoe Richard W (Director, Executive Chairman)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-10	Stock Option (right to buy)	$9.10	A	100000	Acquired	2031-11-09	Common Stock (100000)	Direct

Footnotes

F1: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan").

F2: 50% of the shares will vest in four equal annual installments beginning on November 10, 2022, subject to Reporting Person's continued service as of each such vesting date; the remaining 50% of the shares will vest upon the closing of the earlier of (x) a "Change in Control" (as defined in the Plan) of the Company or (y) a transformative business development transaction, as determined in the discretion of the Board of Directors (together, the "Transactions"); provided that the definitive agreement for either of the Transactions is executed on or prior to November 10, 2022 and the Reporting Person is, immediately prior to the time of the closing of either of the Transactions, still serving as Executive Chairman or as another executive officer. All unvested outstanding time-based options granted to the Reporting Person, shall accelerate so as to be fully vested and immediately exercisable immediately prior to any Change in Control of the Company.